Clinical microbiology has experienced an unprecedented wave of innovation due to the introduction of advanced testing such as PCR, MALDI-TOF, and PNA-FISH. The wave of new technologies has dramatically improved the time to pathogen identification result from culture, but has not impacted antimicrobial susceptibility testing: the definitive diagnostic result for changing antibiotic therapy in patients with bloodstream infections. This presentation explores the clinical need for faster phenotypic susceptibility testing using the Accelerate PhenoTest™ BC kit. Topics covered include the benefits to the patient and the economic benefits to the healthcare institution.
Staphylococcus (Staph Infection)
Medical Laboratory Technician67%
Manufacturer - Other33%